Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMPRT vs Standard RT with Temozolomide for Newly Diagnosed MGMT-Unmethylated Glioblastoma
NCT07452458Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Jul 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) (2 arms), sponsored by NRG Oncology. Primary endpoint: Neurocognitive function. Started Jul 2026; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07452458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07452458.